查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015190

陣發性睡眠性血尿症治療市場：治療方法、給藥頻率、給藥途徑、治療階段、劑量、最終用戶和分銷管道分類－2026-2032年全球市場預測

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment Class, Administration Frequency, Route of Administration, Line of Therapy, Dosage Strength, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，陣發性睡眠性血尿症治療市場價值將達到 58.4 億美元，到 2026 年將成長至 62.5 億美元，到 2032 年將達到 95.5 億美元，複合年成長率為 7.27%。

主要市場統計數據
基準年 2025 58.4億美元
預計年份：2026年 62.5億美元
預測年份 2032 95.5億美元
複合年成長率 (%) 7.27%

陣發性睡眠性血尿症的臨床和策略背景，以及為何相關人員應優先考慮綜合治療途徑。

陣發性睡眠性血尿症是一種罕見的後天性血液系統疾病，在臨床、保險公司和患者群體中都面臨持續的診斷和治療挑戰。其病理生理特徵為補體依賴性血管內溶血和骨髓功能障礙，導致患者需要除急性治療外的複雜護理。患者常常面臨長期輸血依賴、血栓形成風險和進行性性器官損傷等多重負擔，因此，涵蓋專科醫療中心、社區醫院和居家照護的綜合護理路徑至關重要。

近期科學進步、保險公司期望的改變以及以病人為中心的照護模式如何重塑罕見血液疾病的治療模式。

陣發性睡眠性血尿症的治療模式正受到一系列相互關聯的變化的影響，這些變化共同改變了臨床應用標準和市場策略。補體生物學的進展和標靶抑制劑的成熟拓寬了治療選擇的範圍。同時，基因修飾方法的創新有望實現造血功能的持續改善。這些科學進步正在推動以門診管理和居家治療為優先的服務模式的創新，進而影響著與支付方和通路的合約動態。

評估 2025 年美國關稅對供應鏈、價格趨勢以及患者獲得複雜生物製藥和先進療法的累積影響。

美國2025年實施的關稅措施對整個複雜生物製藥和先進細胞及基因療法的供應鏈產生了連鎖反應，影響了定價、生產本地化以及患者獲取藥物的途徑。進口關稅的提高推高了關鍵原料、特殊試劑和成品生物製藥這些產品通常透過全球供應鏈生產。成本上漲迫使製造商重新思考定價策略，接受更低的利潤率，或調整生產基地以降低風險。

將基於證據的細分見解與治療分類、劑量頻率、通路和患者環境聯繫起來，從而與商業策略相結合。

對陣發性睡眠性血尿症治療領域的詳細細分揭示了該領域特有的機會和限制因素，這些都應指導策略優先排序。從治療角度來看，該市場包括補體指南（包括已上市的單株抗體療法，如Eculizumab和拉維珠單抗）、利用慢病毒平台的基因療法（例如 LentiGlobin 技術）以及支持性治療（包括輸血和鐵螯合療法）。每種治療方案都具有獨特的提案：補體抑制劑可有效控制血管內溶血，基因療法有望實現緩解疾病，而支持性治療對於症狀管理和減少合併症仍然至關重要。

區域策略展望，詳細介紹全球主要市場在臨床導入模式、法規環境和准入途徑的差異。

區域趨勢對陣發性睡眠性血尿症的臨床應用、監管路徑以及患者獲得治療的機會有著顯著影響，因此需要製定針對特定區域的策略，以充分考慮各地區不同的支付方環境和醫療基礎設施。在美洲，先進的專科醫療網路、完善的高成本生物製藥報銷機制以及不斷擴展的家庭輸液治療系統，為補體抑製劑和新興的基因修飾療法創造了有利的環境，儘管支付方的審查依然嚴格。在歐洲、中東和非洲地區，多種因素，包括部分歐洲市場的集中法律規範、各國不同的報銷政策以及中東和非洲部分地區的基礎設施挑戰，都可能阻礙複雜治療方法的快速推廣。

領先的開發商、創新者和服務供應商的競爭定位和策略舉措，塑造了治療方法方案和商業化策略。

陣發性睡眠性血尿症治療領域的競爭格局由成熟的生物製藥公司、靈活的臨床階段創新企業以及提供分銷和居家給藥服務供應商共同構成。成熟的補體抑制劑研發企業已建立起穩固的臨床產品組合，並在醫療專業人士中享有盛譽，這為新進入者設定了很高的准入門檻，除非他們能夠提供明顯的差異化優勢，例如延長給藥間隔、提高安全性或簡化給藥方式。同時，致力於基因治療策略的臨床階段公司正在改變該領域的長期前景，他們展現出的持續療效有望減輕患者終身治療的負擔。

在政策環境不斷變化的情況下，產業領導者需要有針對性、可操作性和策略性的行動，以加速採用、最佳化交付模式並確保獲得服務。

行業領導者應著力解決一系列有針對性、可操作的挑戰，將科學進步轉化為持續的患者獲益和永續的商業性回報。首先，他們應優先考慮透過投資長期、真實世界的資料集來創建能夠引起支付方共鳴的證據，這些資料集應量化輸血依賴、血栓事件以及整體醫療資源利用率的降低。這需要結合前瞻性註冊研究設計和能夠捕捉患者報告的益處和生活品質改善的結局指標。

透明的調查方法，總結了用於產生可靠且可操作見解的數據檢驗、專家參與和分析框架。

本分析所依據的研究結合了結構化的二級和一級定性研究，以期獲得廣度和深度兼具的洞察。二級資訊來源包括同行評審的臨床文獻、監管公告以及公開的產品標籤和指導文件，這些資料被整合起來，以建立可靠的臨床和監管基準。一級研究包括對血液學專家、專科藥房負責人、支付方醫療保健經理以及患者權益倡導組織代表的深度訪談，以捕捉包括治療偏好、就醫障礙以及對循證醫學的期望等細微差別在內的觀點。

摘要重點闡述了關鍵轉折點、相關人員的責任以及邁向以病人為中心的永續照護模式的藍圖。

總之，陣發性睡眠性血尿症正處於科學創新與營運和政策挑戰交會的十字路口。雖然補體抑制劑仍能有效控制臨床症狀，但基因改造方法有望為特定患者群體提供長期治癒疾病的方案。然而，為了充分發揮這些進展的潛力，製藥公司、醫療服務提供者、支付方和服務合作夥伴之間必須通力合作，以協調證據生成、交付模式和可及性策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：陣發性睡眠性血尿症治療市場：依治療方法

  • 補體抑制劑
    • Eculizumab
    • 洛維茲瑪
  • 基因治療
  • 支持性護理
    • 輸血
    • 鐵螯合療法

第9章：陣發性睡眠性血尿症治療市場：依給藥頻率分類

  • 每 8 週
  • 每兩週

第10章：陣發性睡眠性血尿症治療市場：依給藥途徑分類

  • 靜脈注射
  • 皮下注射

第11章：陣發性睡眠性血尿症治療市場：依治療階段分類

  • 一線治療
  • 二線治療
  • 三線療法

第12章：陣發性睡眠性血尿症治療市場：依劑量分類

  • 高劑量
  • 低劑量
  • 標準劑量

第13章：陣發性睡眠性血尿症治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第14章：陣發性睡眠性血尿症治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：陣發性睡眠性血尿症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：陣發性睡眠性血尿症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：陣發性睡眠性血尿症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國：陣發性睡眠性血尿症的治療市場

第19章 中國：陣發性睡眠性血尿症治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Akari Therapeutics Plc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Swedish Orphan Biovitrum AB
Product Code: MRR-036C5CF3B54F

The Paroxysmal Nocturnal Hemoglobinuria Treatment Market was valued at USD 5.84 billion in 2025 and is projected to grow to USD 6.25 billion in 2026, with a CAGR of 7.27%, reaching USD 9.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.84 billion
Estimated Year [2026] USD 6.25 billion
Forecast Year [2032] USD 9.55 billion
CAGR (%) 7.27%

Framing the clinical and strategic context of paroxysmal nocturnal hemoglobinuria and why stakeholders must prioritize integrated therapeutic pathways

Paroxysmal nocturnal hemoglobinuria is a rare, acquired hematologic disorder that poses persistent diagnostic and therapeutic challenges across clinical, payer, and patient communities. Its pathophysiology, driven by complement-mediated intravascular hemolysis and bone marrow dysfunction, gives rise to complex care needs that extend beyond acute treatment episodes. Patients often experience burdens that include chronic transfusion dependence, thrombotic risk, and progressive organ damage, which together mandate an integrated care pathway that spans specialty centers, community hospitals, and home-based services.

Clinicians and commercial stakeholders must balance immediate clinical benefit against long-term disease modification potential, while payers and health systems increasingly demand real-world evidence demonstrating sustained outcomes and cost-effectiveness. Treatment decisions hinge not only on efficacy but also on administration frequency, route of delivery, and the logistics of chronic therapy management. As a result, strategic planning for therapeutics and services must consider both clinical endpoints and operational feasibility in diverse care settings.

This introduction frames the subsequent analysis by underscoring the interplay between scientific innovation, care delivery models, and access constraints. It establishes the groundwork for exploring how shifting therapeutic modalities and external policy forces are converging to redefine priorities for manufacturers, providers, and patients alike. The intent is to equip decision-makers with a clear baseline from which to interpret transformational trends and tactical recommendations presented in the following sections.

How recent scientific breakthroughs, shifting payer expectations, and patient-centered care models are reshaping therapeutic paradigms for rare hematologic disorders

The landscape for treating paroxysmal nocturnal hemoglobinuria is being reshaped by multiple, interdependent shifts that together alter the calculus for clinical adoption and market strategy. Advances in complement biology and the maturation of targeted inhibitors have extended the spectrum of therapeutic options, while parallel innovations in gene-modifying approaches promise the possibility of durable hematopoietic correction. These scientific advances are being accompanied by service-model innovations that prioritize outpatient management and home-based administration, which in turn influence payer contracting and channel dynamics.

At the same time, payer expectations are evolving from episodic coverage of high-cost infusions toward performance-based arrangements and outcomes-linked reimbursement. Payers are scrutinizing not only clinical efficacy but also total cost of care, patient-reported outcomes, and the capacity for therapies to reduce downstream complications such as thrombosis and transfusion dependence. This shift compels manufacturers to demonstrate longitudinal benefit through both clinical trials and robust real-world evidence programs.

The patient voice is gaining influence, driving manufacturers and providers to optimize treatment convenience, reduce infusion burden, and expand access through telehealth-enabled follow-up and home infusion frameworks. Collectively, these transformative dynamics demand that stakeholders adopt integrated commercialization and clinical strategies that align therapeutic differentiation with pragmatic delivery solutions and payer-aligned evidence generation.

Assessing the cumulative implications of United States tariffs in 2025 on supply chains, pricing dynamics, and patient access for complex biologics and advanced therapies

The introduction of tariff measures in the United States during 2025 has produced cascading effects across the supply chains supporting complex biologics and advanced cell and gene therapies, with implications for pricing, manufacturing localization, and patient access. Increased import tariffs raise direct input costs for critical raw materials, specialized reagents, and finished biologic products that are often manufactured through global supply chains. These elevated costs pressure manufacturers to reassess pricing strategies, absorb margin erosion, or reconfigure production footprints to mitigate exposure.

In response, some developers may accelerate investments in domestic manufacturing capability or pursue near-shoring for critical components to reduce tariff risk and shorten logistical lead times. Such strategic reorientation requires capital and time but can yield supply resilience and improved responsiveness to demand variability. Meanwhile, distributors and specialty pharmacies face increased operational complexity as they navigate patchworked tariff implications across product categories and sourcing channels, which may alter channel economics and push certain therapies toward consolidated distribution models.

For patients and providers, cumulative tariff-driven cost pressures can manifest as tighter payer coverage policies, heightened utilization management, or increased out-of-pocket exposure where benefit design permits. Payers may demand stronger evidence of comparative effectiveness and demonstrable reductions in downstream resource use before extending broad coverage. Consequently, manufacturers should proactively engage payers with value dossiers that contextualize clinical benefit, demonstrate care pathways that reduce ancillary costs, and propose risk-sharing constructs that spread exposure. In parallel, contingency planning for manufacturing and supply continuity, including dual-sourcing strategies and regional inventory buffers, will be essential to maintain patient access in the face of tariff volatility.

An evidence-driven segmentation insight synthesis linking treatment class, administration frequency, distribution channel, and patient settings to commercial strategy

Deep segmentation of the paroxysmal nocturnal hemoglobinuria therapeutic landscape reveals differentiated opportunities and constraints that should inform strategic prioritization. When viewed through treatment class, the market comprises complement inhibitors, which include well-established monoclonal antibody therapies such as eculizumab and ravulizumab; gene therapies that are leveraging lentiviral platforms exemplified by LentiGlobin approaches; and supportive therapies encompassing blood transfusion and iron chelation therapy. Each class carries distinct value propositions: complement inhibitors offer predictable control of intravascular hemolysis, gene therapies promise durable disease modification, and supportive measures remain essential for symptomatic management and comorbidity mitigation.

Administration frequency is a pivotal determinant of patient convenience and health-system resource use, with regimens administered every eight weeks offering clear logistics advantages compared with therapies requiring dosing every two weeks. Distribution channels shape commercial access and patient experience, with hospital pharmacy environments providing integrated specialty care, online pharmacy channels enabling home delivery and convenience, and retail pharmacies offering geographic accessibility and rapid dispensing. End-user dynamics further nuance adoption patterns: home care settings enable decentralized administration and can reduce institutional costs; hospitals remain the fulcrum for initiation and management of complex cases; and specialty clinics act as centers of excellence for advanced therapies.

Route of administration differentiates clinical workflows, contrasting intravenous administration that requires infusion infrastructure with subcutaneous administration that favors outpatient or self-administration. Line-of-therapy considerations-spanning first line through third line-drive clinical sequencing and payer coverage thresholds, while dosage strength segments such as high dose, low dose, and standard dose influence safety monitoring, manufacturing complexity, and reimbursement negotiation. Integrating these segmentation layers yields a multidimensional view of where therapeutic and commercial investments will deliver the greatest strategic returns.

Regional strategic outlook detailing differential clinical adoption patterns, regulatory environments, and access pathways across key global markets

Regional dynamics materially influence clinical adoption, regulatory pathways, and patient access for paroxysmal nocturnal hemoglobinuria therapies, necessitating region-specific strategies that acknowledge distinct payer landscapes and care delivery infrastructures. In the Americas, advanced specialty care networks, established reimbursement frameworks for high-cost biologics, and growing home infusion capabilities create a receptive environment for both complement inhibitors and emerging gene-modifying therapies, although payer scrutiny remains rigorous. Europe, Middle East & Africa presents a heterogeneous mix of centralized regulatory oversight in some European markets, variable reimbursement timelines across countries, and limited infrastructure challenges in parts of the Middle East and Africa that can impede rapid adoption of complex therapies.

The Asia-Pacific region offers rapid patient demand growth and diverse regulatory regimes, with some countries accelerating approvals for innovative therapies while others require extended local evidence generation and pricing negotiations. Across all regions, differences in hospital capacity, prevalence of specialty infusion centers, and maturity of specialty pharmacy networks drive variations in channel strategy and patient support program design. Stakeholders must therefore adopt a layered regional approach that combines global clinical evidence with locally grounded health economic models, targeted stakeholder engagement plans, and adaptable distribution models to ensure both uptake and sustainability of advanced therapeutic options.

Competitive positioning and strategic moves by leading developers, innovators, and service providers shaping therapeutic choices and commercialization strategies

Competitive dynamics in paroxysmal nocturnal hemoglobinuria treatment are shaped by a combination of established biologic incumbents, nimble clinical-stage innovators, and service providers that enable distribution and home administration. Established complement inhibitor developers have built durable clinical portfolios and provider familiarity, creating high barriers for new entrants unless they deliver meaningful differentiation such as extended dosing intervals, improved safety profiles, or simpler administration. At the same time, clinical-stage companies pursuing gene therapy strategies are changing the long-term conversation by presenting the potential for durable responses that could reduce lifetime treatment burden.

Service providers, specialty pharmacies, and integrated care networks are equally important, as they operationalize delivery models that influence patient adherence and real-world outcomes. Partnerships across manufacturers and service providers are increasingly central to launch plans, as coordinated approaches to training, patient support, and reimbursement navigation are required for complex therapies. For companies evaluating their positioning, the key is to align clinical differentiation with pragmatic delivery models and payer-focused evidence generation, while remaining flexible to form alliances that accelerate market entry and scale.

Targeted, practical strategic actions for industry leaders to accelerate adoption, optimize delivery models, and safeguard access amid evolving policy landscapes

Industry leaders should pursue a set of targeted, actionable imperatives to translate scientific advances into durable patient benefit and sustainable commercial returns. First, prioritize evidence generation that resonates with payers by investing in longitudinal real-world datasets that quantify reductions in transfusion dependence, thrombotic events, and overall healthcare utilization. This should be paired with prospective registry designs and outcomes measures that capture patient-reported benefits and quality-of-life improvements.

Second, optimize product differentiation through operational advantages such as extending administration intervals and enabling subcutaneous or home-based delivery where clinically appropriate, thereby reducing care burden and improving adherence. Third, strengthen distribution resilience by implementing dual-sourcing for critical inputs, evaluating regional manufacturing options, and partnering with specialty pharmacies to streamline home administration and patient support. Fourth, proactively engage payers with innovative contracting approaches, including outcomes-based arrangements that share risk and demonstrate value alignment. Fifth, develop modular launch playbooks that can be localized for the Americas, Europe, Middle East & Africa, and Asia-Pacific, accounting for regulatory idiosyncrasies and channel maturity. Finally, invest in clinician and patient education to foster early diagnosis and timely therapeutic escalation, ensuring that novel therapies reach the patients most likely to benefit while minimizing inappropriate utilization.

Transparent research methodology summarizing data triangulation, expert engagement, and analytical frameworks used to produce robust actionable insights

The research underpinning this analysis combines structured secondary research with primary qualitative engagement to ensure both breadth and depth of insight. Secondary sources included peer-reviewed clinical literature, regulatory communications, and publicly available product labeling and guidance documents, which were synthesized to establish a robust clinical and regulatory baseline. Primary research comprised in-depth interviews with hematology specialists, specialty pharmacy leaders, payer medical directors, and patient advocacy representatives to capture nuanced perspectives on treatment preferences, access barriers, and evidence expectations.

Analytical methods included cross-segmentation mapping to reveal intersectional insights across treatment class, administration frequency, distribution channels, end-user settings, route of administration, line of therapy, and dosage strength. Scenario analysis was applied to evaluate the potential operational and commercial outcomes of tariff-related supply disruptions and to stress-test pricing and access strategies under variable reimbursement conditions. Triangulation of evidence was used throughout to reconcile differences between controlled-trial efficacy and real-world effectiveness, and limitations are acknowledged where emerging modalities such as gene therapies have limited longitudinal data. The methodology emphasizes transparency and reproducibility, enabling stakeholders to understand the assumptions that underlie strategic recommendations.

Concluding synthesis highlighting critical inflection points, stakeholder responsibilities, and the roadmap toward durable patient-centric care models

In closing, the paroxysmal nocturnal hemoglobinuria landscape is at an inflection point where scientific innovation intersects with operational and policy challenges. Complement inhibitors continue to provide meaningful clinical control, while gene-modifying approaches hold the promise of long-term correction for select patient populations. Yet realizing the full potential of these advances depends on coordinated efforts across manufacturers, providers, payers, and service partners to align evidence generation, delivery models, and access strategies.

Stakeholders that proactively address administration convenience, supply chain resilience, and payer-aligned evidence generation will be best positioned to convert clinical promise into sustained patient benefit. The convergence of home-care enablement, outcomes-focused reimbursement, and regional regulatory evolution creates openings for differentiated programs that reduce total cost of care while enhancing patient quality of life. Ultimately, the roadmap to improved outcomes combines rigorous science with pragmatic operational design and collaborative payer engagement, ensuring that therapeutic advances translate into measurable improvements for patients living with paroxysmal nocturnal hemoglobinuria.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment Class

  • 8.1. Complement Inhibitors
    • 8.1.1. Eculizumab
    • 8.1.2. Ravulizumab
  • 8.2. Gene Therapies
  • 8.3. Supportive Therapies
    • 8.3.1. Blood Transfusion
    • 8.3.2. Iron Chelation Therapy

9. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Administration Frequency

  • 9.1. Every Eight Weeks
  • 9.2. Every Two Weeks

10. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Route of Administration

  • 10.1. Intravenous Administration
  • 10.2. Subcutaneous Administration

11. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Line of Therapy

  • 11.1. First Line
  • 11.2. Second Line
  • 11.3. Third Line

12. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Dosage Strength

  • 12.1. High Dose
  • 12.2. Low Dose
  • 12.3. Standard Dose

13. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by End User

  • 13.1. Home Care Settings
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market

19. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Akari Therapeutics Plc
  • 20.6. Alnylam Pharmaceuticals, Inc.
  • 20.7. Amgen Inc.
  • 20.8. Apellis Pharmaceuticals, Inc.
  • 20.9. AstraZeneca plc
  • 20.10. F. Hoffmann-La Roche Ltd.
  • 20.11. Genentech, Inc.
  • 20.12. Novartis AG
  • 20.13. Regeneron Pharmaceuticals, Inc.
  • 20.14. Samsung Bioepis Co., Ltd.
  • 20.15. Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 180. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 206. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 210. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 216. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 220. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)